Associated tags: KIT, KDR, FGF, Everolimus, Lenvatinib, VEGFR1, FLT4, VEGF, Hepatocellular carcinoma, VEGFR3, FGFR, Eisai, RET, FLT1
Retrieved on:
Thursday, January 18, 2024
Senior,
Role,
Renal cell carcinoma,
Patient,
Research,
Meta-analysis,
Rescue coordination centre,
RCC,
ASCO,
Everolimus,
Pivotal,
Society,
Apoptosis,
Disease,
Safety,
Eisai,
FDA,
Abstract,
Pharmaceutical industry NUTLEY, N.J., Jan. 18, 2024 /PRNewswire/ -- Eisai announced today the presentation of research in renal cell carcinoma (RCC) during the 2024 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium (#GU24) which is taking place in-person in San Francisco, California and online from January 25-27. Notable presentations include a rapid oral abstract session featuring subgroup analyses from the pivotal Phase 3 CLEAR (Study 307)/KEYNOTE-581 trial, which evaluated lenvatinib (LENVIMA®), the orally available multiple receptor tyrosine kinase inhibitor discovered by Eisai, plus pembrolizumab (KEYTRUDA®), Merck's anti-PD-1 therapy, versus sunitinib for the first-line treatment of patients with advanced renal cell carcinoma (aRCC) (NCT02811861; Abstract: #364).
Key Points:
- We look forward to engaging in critical scientific exchange to improve outcomes for these patients."
- A network meta-analysis to assess the efficacy of lenvatinib plus pembrolizumab compared with other first-line treatment options for patients with aRCC will be shared in a poster session (Abstract: #482).
- There is no guarantee that any investigational compounds or investigational uses of FDA-approved products will successfully complete clinical development or gain FDA approval.
- These abstracts will be made available via the ASCO website on Monday, January 22, 2024, at 5:00 PM EST (2:00 PM PST).
Retrieved on:
Tuesday, January 16, 2024
Senior,
Patient,
HCC,
Research,
Neoplasm,
ASCO,
Society,
Liver cancer,
FGFR2,
Hepatocellular carcinoma,
Apoptosis,
CBP,
Safety,
Abstract,
FDA,
Gastrointestinal cancer,
CREB-binding protein,
Biomarker,
Merck,
LEAP,
TKI,
Pharmaceutical industry NUTLEY, N.J., Jan. 16, 2024 /PRNewswire/ -- Eisai announced today the presentation of gastrointestinal cancer research during the 2024 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium (#GI24), which is taking place in-person in San Francisco, California and virtually from January 18-20.
Key Points:
- "We look forward to convening in San Francisco to share longer-term efficacy and safety results from the Phase 3 LEAP-002 trial with the scientific community at ASCO GI 2024.
- Tasurgratinib, for which a marketing authorization application was submitted in Japan in December 2023, is an orally available selective TKI of FGFR1-3.
- There is no guarantee that any investigational compounds or investigational uses of FDA-approved products will successfully complete clinical development or gain FDA approval.
- These abstracts will be made available via the ASCO website on Tuesday, January 16, 2024, at 5:00 PM EST (2:00 PM PST).
CREB-binding protein,
Carcinoma,
Abstract,
Senior,
CBP,
Cancer,
Research,
Trial of the century,
ASCO,
American Society of Clinical Oncology,
Patient,
Physician,
Sorafenib,
Oncology nursing,
Annual general meeting,
ADC,
Poster,
FDA,
Survival analysis,
Society,
HCC,
Safety,
Nivolumab,
Pharmaceutical industry,
Eisai NUTLEY, N.J., May 23, 2023 /PRNewswire/ -- Eisai announced today the presentation of research across various types of cancer from its oncology portfolio and pipeline during the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting (#ASCO23), which is taking place virtually and in-person in Chicago, Illinois from June 2 to 6.
Key Points:
- Eisai entered into a joint development agreement with BlissBio for BB-1701 with option rights for a strategic collaboration in April 2023.
- A Phase 1/2 clinical study of BB-1701 in the U.S. and China for HER2-expressing solid tumors is currently underway.
- There is no guarantee that any investigational compounds or investigational uses of FDA-approved products will successfully complete clinical development or gain FDA approval.
- These abstracts will be made available on Thursday, May 25, 2023 at 5:00 PM EDT.
Retrieved on:
Wednesday, January 18, 2023
NUTLEY, N.J., Jan. 18, 2023 /PRNewswire/ -- Eisai announced today the presentation of research across various types of gastrointestinal cancers during the 2023 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium (#GI23), which is taking place in-person in San Francisco, California and virtually from January 19-21.
Key Points:
Highlights Include an Update from the Dose Escalation Part of a Phase 1 Study Evaluating the Novel Anticancer Agent, E7386, in Advanced Solid Tumors Including Colorectal Cancer
